Trevi Therapeutics, Inc.
trevitherapeutics.comWhat Do They Do?
Develops Haduvio, an investigational oral therapy for chronic cough in patients with idiopathic pulmonary fibrosis, other interstitial lung diseases, and refractory chronic cough.
10-K for FY2025, filed Mar 17, 2026We are a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio…View ↗
Non-IPF ILD-related Chronic Cough Program. We also plan to develop Haduvio for the treatment of non-IPF ILD-related chronic cough. Many…View ↗
RCC Program. We are developing Haduvio for the treatment of RCC, which affects approximately 2-3 million adults in the U.S. and is related…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$17.8MView ↗
- ▲ +45% (Loss)
- vs −$12.3M in Q2 FY2025
-
Apr 17, 2026
Priced an underwritten common-stock offering
Trevi priced an offering of its common stock, with all shares sold by the company.
Sources
8-K, filed Apr 17, 2026
New Haven, Conn., April 16, 2026 – Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the…View ↗
Program focus
The older report included prurigo nodularis among Haduvio's target conditions, while the latest report describes development for chronic cough associated with idiopathic pulmonary fibrosis, other interstitial lung diseases, and refractory chronic cough.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 17, 2026We are a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio…View ↗
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio…View ↗
Non-IPF ILD-related Chronic Cough Program. We also plan to develop Haduvio for the treatment of non-IPF ILD-related chronic cough. Many…View ↗
RCC Program. We are developing Haduvio for the treatment of RCC, which affects approximately 2-3 million adults in the U.S. and is related…View ↗
Who Do They Compete With?
Competes with GSK, Merck, and Nocion Therapeutics
10-K for FY2025, filed Mar 17, 2026If Haduvio is approved for the treatment of patients with RCC, we expect that it may compete with product candidates in clinical…View ↗
Loading...
